Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-girentuximab in Advanced Renal Cell Cancer
NCT02002312Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2011
- Primary completion
- Jun 2015
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of 177-Lu-DOTA-cG250 in clear cell renal cell carcinoma (ccRCC), sponsored by Radboud University Medical Center. Started Aug 2011; status: completed.
02
Drugs
177-Lu-DOTA-cG250
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT02002312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02002312.